M42 and Cleveland Clinic Abu Dhabi partners with Toshiba Energy Systems & Solutions Corporation to build Middle East's first heavy-ion therapy facility for cancer treatment in Abu Dhabi
ABU DHABI (ALETIHAD)M42 is set to build a heavy ion therapy facility at Cleveland Clinic Abu Dhabi, bringing one of the most advanced and effective cancer treatment technologies to the Middle East and positioning Abu Dhabi as a global leader in oncology innovation and care. The announcement was made during Abu Dhabi Global Health Week (ADGHW) 2025, a major government initiative by the Department of Health – Abu Dhabi (DoH) that seeks to advance the future of health and wellbeing.With no heavy ion therapy centre within a five-hour flight radius of the UAE, this facility ensures patients from across the region can access world-class care. The advanced form of radiation therapy will deliver unparalleled precision in targeting and destroying cancerous tumours with greater efficacy, revolutionising cancer treatment, and filling a critical gap in advanced care options for patients in the UAE and the broader region.Construction of the new facility will begin in 2026 at the Cleveland Clinic Abu Dhabi (CCAD) campus, adjacent to the recently launched Fatima bint Mubarak Center, a first-of-its-kind cancer centre that delivers a multidisciplinary approach to cancer care. The heavy-ion therapy system will include one treatment room equipped with a rotating gantry and one horizontally fixed beam treatment room. The system incorporates cutting-edge high-speed scanning irradiation technology, and a compact rotating gantry equipped with superconducting magnets.Together with the Fatima bint Mubarak Center, the state-of-the-art facility further underscores CCAD's position as a leader in oncology advancements and personalised care, offering a comprehensive and multidisciplinary approach to cancer treatment, under one roof.The first heavy ion therapy system in the region follows a strategic partnership between M42 and Toshiba Energy Systems & Solutions Corporation (Toshiba ESS). The collaboration combines M42's expertise in healthcare innovation with Toshiba ESS's technological advancements in particle therapy, positioning Abu Dhabi as a hub for cutting-edge cancer treatment.The agreement was recently signed in the UAE by Hasan Jasem Al Nowais, Managing Director and Group Chief Executive Officer of M42, and Chairman of CCAD, alongside Tsutomu Takeuchi, Director, Vice President for Power Systems Division, and Chief Nuclear Officer of Toshiba ESS, marking a significant milestone in the region's healthcare evolution.Al Nowais said, "M42's partnership with Toshiba ESS is a significant step that reinforces our commitment to reshaping the future of global health through cutting-edge innovations and technologies. By introducing heavy ion therapy to the Middle East, we are not only enhancing Cleveland Clinic Abu Dhabi's oncology capabilities but also plugging in a critical gap in cancer treatment options for people in the region. With no other heavy ion radiotherapy center within a five-hour flight radius of Abu Dhabi, this advanced, accurate and effective form of radiation therapy gives hope to cancer sufferers in the region."Takeuchi said, 'Toshiba has always been at the forefront of technological innovation for societal benefit. We are thrilled to partner with M42 to transform cancer treatment in the Middle East region. Heavy ion therapy represents a significant leap forward in radiation therapy, offering faster and less frequent treatments. We look forward to seeing the positive impact this technology will have on cancer patients' lives.'Chief Executive Officer of CCAD, Dr Georges-Pascal Haber, said, "At Cleveland Clinic Abu Dhabi, we are dedicated to bringing the world's most advanced cancer treatment modalities to our patients. The introduction of heavy ion therapy is a testament to our relentless pursuit of innovation and excellence in oncology. By integrating this cutting-edge technology into our cancer care programme, we are not only enhancing treatment outcomes but also providing hope to patients across the globe facing some of the most challenging cancer diagnoses. This milestone solidifies our position as a global leader in personalised, patient-centered oncology care."Heavy ion therapy is globally acclaimed for its superior physical and radiobiological properties compared to traditional photon-based therapies. The advanced treatment delivers higher doses of radiation directly to tumours while minimising damage to surrounding healthy tissues.Key benefits include shorter, less frequent treatment sessions, significantly reducing the overall burden on patients. For instance, early-stage lung cancer can be treated in a single outpatient session.Additionally, heavy ion therapy is particularly effective for treating tumours that are inoperable or resistant to conventional therapies, including large tumours and liver metastases. Moreover, it lowers the risk of secondary cancers, offering patients a more effective initial treatment and a safer long-term prognosis.With only 15 centres worldwide offering heavy ion radiotherapy, the addition of this therapy to the Fatima bint Mubarak Center will position the region at the forefront of global oncology services.
The development ensures the most advanced radiation therapy is available to patients in the UAE and beyond, marking a significant milestone in cancer treatment innovation.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Arabian Business
a day ago
- Arabian Business
Abu Dhabi launches newborn genetic screening programme to detect 815 childhood conditions
The Department of Health – Abu Dhabi (DoH) has launched the Newborn Genetic Screening Programme, one of the most comprehensive of its kind globally, offering whole genome sequencing to screen for more than 815 treatable childhood genetic conditions. The initiative, launched in alignment with the Emirati Genome Council's vision for personalised and precision healthcare, marks a step towards genomics-driven medicine in the UAE. It enables early detection, tailored interventions, and improved health outcomes for newborns. In its first phase, the programme has been introduced at Kanad Hospital and Danat Al Emarat Hospital, in partnership with M42, as a voluntary option. It is set to expand across all maternity hospitals in the emirate to cover UAE nationals and children of Emirati mothers. By testing cord blood samples at birth with parental consent, the programme screens for metabolic disorders, immunodeficiencies, hematologic conditions, and rare diseases such as spinal muscular atrophy, which can be treated with gene therapy. Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, said: 'Healthcare begins long before symptoms appear, and today, empowered by science and technology, we can act earlier than ever before. This programme reflects Abu Dhabi's commitment to leveraging innovation to serve our community, starting from the first days of life. Through early detection, personalised care, and strategic foresight, we are building a future of healthier generations and reinforcing Abu Dhabi's position as a global leader in proactive, precision healthcare.' Dr. Mohamed Al Ameri, Acting Director of Genome and Biobank Division, Department of Health – Abu Dhabi, said: 'As we work to integrate genomics into our preventative healthcare infrastructure, we aim to expand this initiative to all maternity hospitals in the emirate, demonstrating how genomics can reshape healthcare, shifting from a one-size-fits-all model to a precise, proactive, and personalised approach that improves patient outcomes.' To support the rollout, DoH held workshops with stakeholders to review the gene panel and patient journey, and trained 16 paediatricians and neonatologists on genetic counselling practices. Results are reported within 21 days, with genetic counselling and referrals provided if actionable findings are identified. The Newborn Genetic Screening Programme builds on initiatives under the Emirati Genome Programme, including premarital screening, and is part of a broader strategy to integrate genomics into family health to reduce the prevalence of genetic diseases and support informed decision-making.
Dubai Eye
3 days ago
- Dubai Eye
Abu Dhabi launches newborn genetic testing programme
Abu Dhabi has rolled out a newborn genetic screening programme for Emirati nationals across several hospitals, to enable early detection and diagnosis of genetic conditions. The Newborn Genetic Screening Programme offers whole genome sequencing to screen more than 815 treatable childhood genetic conditions, including metabolic disorders, immunodeficiencies, hematologic conditions, and rare diseases such as spinal muscular atrophy. Using genomics and artificial intelligence (AI), the first phase of the programme has been implemented as a voluntary option at Kanad Hospital and Danat Al Emarat Hospital, in partnership with M42. The initiative is planned to be expanded across all maternity hospitals to screen UAE nationals and children of Emirati mothers born in the emirate. By collecting and testing cord blood samples at birth, with parental consent, healthcare providers can identify conditions that may not be apparent at birth but could significantly affect a child's health if treatment is delayed. Results are reported within 21 days, and parents will receive genetic counselling and be referred to multidisciplinary specialists if any actionable findings are identified. 'Through early detection, personalised care and strategic foresight, we are building a future of healthier generations and reinforcing Abu Dhabi's position as a global leader in proactive, precision healthcare," said Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi. To support the rollout of the programme, DoH conducted a workshop to review the gene panel and patient journey with specialists from stakeholders across Abu Dhabi. DoH also collaborated with M42 to train 16 paediatricians and neonatologists across three maternity hospitals, Corniche Hospital, Danat Al Emarat and Kanad Hospital, on genetic counselling practices and the importance of newborn genetic screening. These initiatives aim to reduce the prevalence of genetic diseases, inform reproductive choices, facilitate access to early intervention, and empower families with vital health information, fostering a future where personalised, preventative healthcare is the standard. The Newborn Genetic Screening Programme is one of several initiatives that have been made possible by the Emirati Genome Programme, such as the Premarital Screening Programme, harnessing the power of genomics and latest technologies to promote informed decisions. These efforts pave the way forward for more precise and effective treatments, ensuring the long-term health and wellbeing of future generations of Emiratis.
TAG 91.1
3 days ago
- TAG 91.1
Abu Dhabi launches newborn genetic testing programme
Abu Dhabi has rolled out a newborn genetic screening programme for Emirati nationals across several hospitals, to enable early detection and diagnosis of genetic conditions. The Newborn Genetic Screening Programme offers whole genome sequencing to screen more than 815 treatable childhood genetic conditions, making it one of the most comprehensive genetic screening programmes for newborns in the world. Using genomics and artificial intelligence (AI), the first phase of the programme has been implemented as a voluntary option at Kanad Hospital and Danat Al Emarat Hospital, in partnership with M42. The initiative is planned to be expanded across all maternity hospitals to screen UAE Nationals and children of Emirati mothers born in the emirate, further strengthening Abu Dhabi's leadership in preventive healthcare and precision medicine. By collecting and testing cord blood samples at birth, with parental consent, healthcare providers can identify conditions that may not be apparent at birth but could significantly affect a child's health if treatment is delayed. The conditions screened under the programme include metabolic disorders, immunodeficiencies, hematologic conditions, and rare diseases such as spinal muscular atrophy, which is treatable by gene therapy. Results are reported within 21 days, and parents will receive genetic counselling and be referred to multidisciplinary specialists if any actionable findings are identified. Her Excellency Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, said: 'Healthcare begins long before symptoms appear, and today, empowered by science and technology, we can act earlier than ever before." Dr. Mohamed Al Ameri, Acting Director of Genome and Biobank Division, Department of Health – Abu Dhabi said: 'As we work to integrate genomics into our preventative healthcare infrastructure, we aim to expand this initiative to all maternity hospitals in the emirate, demonstrating how genomics can reshape healthcare, shifting from a one-size-fits-all model to a precise, proactive, and personalised approach that improves patient outcomes.' To support the rollout of the programme, DoH conducted a workshop to review the gene panel and patient journey with specialists from stakeholders across Abu Dhabi. DoH also collaborated with M42 to train 16 paediatricians and neonatologists across three maternity hospitals, Corniche Hospital, Danat Al Emarat and Kanad Hospital, on genetic counselling practices and the importance of newborn genetic screening. Early detection through this enhanced screening programme allows for timely medical intervention and aligns with Abu Dhabi's broader strategy to integrate genomics into various aspects of family health, including premarital screening and genetic counselling, thus creating a comprehensive, family-centred care ecosystem. These initiatives aim to reduce the prevalence of genetic diseases, inform reproductive choices, facilitate access to early intervention, and empower families with vital health information, fostering a future where personalised, preventative healthcare is the standard. The Newborn Genetic Screening Programme is one of several initiatives that have been made possible by the Emirati Genome Programme, such as the Premarital Screening Programme, harnessing the power of genomics and latest technologies to promote informed decisions. These efforts pave the way forward for more precise and effective treatments, ensuring the long-term health and wellbeing of future generations of Emiratis.
